Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06511388 · ClinicalTrials.gov registry record
Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-dimensional Echocardiographic Speckle Tracking Imaging Study
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 400
- Enrollment target
NCT06511388: Clinical Trial study, sponsored by Mayo Clinic.
NCT06511388 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 400 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06511388 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 400 participants
- Enrollment target
Study Summary
This study is being done to identify markers that will allow researchers to identify in advance patients with sarcomas who are at highest risk for developing heart failure related to chemotherapy.
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2016-01-20 |
| Est. Completion | 2024-10-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06511388
The ClinicalTrials.gov registry entry for NCT06511388 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06511388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06511388 about?
NCT06511388 is a clinical study titled "Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-dimensional Echocardiographic Speckle Tracking Imaging Study". This study is being done to identify markers that will allow researchers to identify in advance patients with sarcomas who are at highest risk for developing heart failure related to chemotherapy.
What is the current status of trial NCT06511388?
This trial is currently terminated. The enrollment target is 400 participants. The study started on 2016-01-20. Estimated completion is 2024-10-09.
What interventions are being tested in trial NCT06511388?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06511388?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.